Your browser doesn't support javascript.
loading
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer, Sofie H; van Wilpe, Sandra; Geerlings, Maartje J; von Rhein, Daniel; Smilde, Tineke J; Kloots, Iris S H; Westdorp, Harm; Coskuntürk, Mustafa; Oving, Irma M; van Ipenburg, Jolique A; van der Heijden, Antoine G; Hofste, Tom; Weiss, Marjan M; Schalken, Jack A; Gerritsen, Winald R; Ligtenberg, Marjolijn J L; Mehra, Niven.
Afiliación
  • Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Wilpe S; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Geerlings MJ; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • von Rhein D; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands.
  • Kloots ISH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Westdorp H; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Coskuntürk M; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands.
  • van Ipenburg JA; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van der Heijden AG; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Hofste T; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Weiss MM; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Gerritsen WR; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Ligtenberg MJL; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Niven.mehra@radboudumc.nl.
Eur Urol Oncol ; 7(2): 282-291, 2024 Apr.
Article en En | MEDLINE | ID: mdl-37673768
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Urol Oncol Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Urol Oncol Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos